Stéphanie Bordenave-Juchereau

Squid gelatin hydrolysates with antihypertensive, anticancer and antioxidant activity

Ailén Alemán, Efrén Pérez‐Santín, Stéphanie Bordenave-Juchereau et al. · Food Research International · 2011 · 231 citations

Life Sciences, Biochemistry, Medicinal Chemistry +11

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

Neal Ready, Clarisse Audigier-Valette, Jonathan W. Goldman et al. · Journal for ImmunoTherapy of Cancer · 2023 · 73 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

Martin Reck, Tudor–Eliade Ciuleanu, Michael Schenker et al. · European Journal of Cancer · 2024 · 73 citations

Medicine, Oncology, Pharmacology +14

Measuring Angiotensin-I Converting Enzyme Inhibitory Activity by Micro Plate Assays: Comparison Using Marine Cryptides and Tentative Threshold Determinations with Captopril and Losartan

Yesmine Ben Henda, Anis Labidi, Ingrid Fruitier‐Arnaudin et al. · Journal of Agricultural and Food Chemistry · 2013 · 64 citations

Medicine, Medicinal Chemistry, Pharmacology +16

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

David P. Carbone, Tudor–Eliade Ciuleanu, Michael Schenker et al. · Journal for ImmunoTherapy of Cancer · 2024 · 62 citations · Full text

Medicine, Oncology, Pharmacology +17